176 related articles for article (PubMed ID: 17724659)
1. Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS.
Chesko J; Kazzaz J; Ugozzoli M; Singh M; O'Hagan DT; Madden C; Perkins M; Patel N
J Pharm Sci; 2008 Apr; 97(4):1443-53. PubMed ID: 17724659
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles.
Chesko J; Kazzaz J; Ugozzoli M; O'hagan DT; Singh M
J Pharm Sci; 2005 Nov; 94(11):2510-9. PubMed ID: 16200615
[TBL] [Abstract][Full Text] [Related]
3. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.
Singh M; Kazzaz J; Chesko J; Soenawan E; Ugozzoli M; Giuliani M; Pizza M; Rappouli R; O'Hagan DT
J Pharm Sci; 2004 Feb; 93(2):273-82. PubMed ID: 14705185
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
5. Charged polylactide co-glycolide microparticles as antigen delivery systems.
Singh M; Kazzaz J; Ugozzoli M; Chesko J; O'Hagan DT
Expert Opin Biol Ther; 2004 Apr; 4(4):483-91. PubMed ID: 15102598
[TBL] [Abstract][Full Text] [Related]
6. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.
Singh M; Chesko J; Kazzaz J; Ugozzoli M; Kan E; Srivastava I; O'Hagan DT
Pharm Res; 2004 Dec; 21(12):2148-52. PubMed ID: 15648244
[TBL] [Abstract][Full Text] [Related]
7. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
Jain S; O'Hagan DT; Singh M
Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176
[TBL] [Abstract][Full Text] [Related]
8. A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery.
Jain S; Malyala P; Pallaoro M; Giuliani M; Petersen H; O'Hagan DT; Singh M
J Pharm Sci; 2011 Feb; 100(2):646-54. PubMed ID: 20665902
[TBL] [Abstract][Full Text] [Related]
9. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems.
Singh M; Kazzaz J; Ugozzoli M; Malyala P; Chesko J; O'Hagan DT
Curr Drug Deliv; 2006 Jan; 3(1):115-20. PubMed ID: 16472100
[TBL] [Abstract][Full Text] [Related]
10. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems.
Delgado A; Lavelle EC; Hartshorne M; Davis SS
Vaccine; 1999 Jul; 17(22):2927-38. PubMed ID: 10438065
[TBL] [Abstract][Full Text] [Related]
11. Surface characteristics of spray-dried microspheres consisting of PLGA and PVP: relating the influence of heat and humidity to the thermal characteristics of these polymers.
Meeus J; Scurr DJ; Amssoms K; Davies MC; Roberts CJ; Van den Mooter G
Mol Pharm; 2013 Aug; 10(8):3213-24. PubMed ID: 23844639
[TBL] [Abstract][Full Text] [Related]
12. The immune response to a model antigen associated with PLG microparticles prepared using different surfactants.
Rafati H; Lavelle EC; Coombes AG; Stolnik S; Holland J; Davis SS
Vaccine; 1997 Dec; 15(17-18):1888-97. PubMed ID: 9413098
[TBL] [Abstract][Full Text] [Related]
13. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol.
Lavelle EC; Yeh MK; Coombes AG; Davis SS
Vaccine; 1999 Feb; 17(6):512-29. PubMed ID: 10075157
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments.
Coombes AG; Tasker S; Lindblad M; Holmgren J; Hoste K; Toncheva V; Schacht E; Davies MC; Illum L; Davis SS
Biomaterials; 1997 Sep; 18(17):1153-61. PubMed ID: 9259512
[TBL] [Abstract][Full Text] [Related]
15. Adsorption of poly(ethylene glycol)-modified ribonuclease A to a poly(lactide-co-glycolide) surface.
Daly SM; Przybycien TM; Tilton RD
Biotechnol Bioeng; 2005 Jun; 90(7):856-68. PubMed ID: 15841471
[TBL] [Abstract][Full Text] [Related]
16. Cationic microparticles are a potent delivery system for a HCV DNA vaccine.
O'Hagan DT; Singh M; Dong C; Ugozzoli M; Berger K; Glazer E; Selby M; Wininger M; Ng P; Crawford K; Paliard X; Coates S; Houghton M
Vaccine; 2004 Dec; 23(5):672-80. PubMed ID: 15542189
[TBL] [Abstract][Full Text] [Related]
17. Limits of detection for time of flight secondary ion mass spectrometry (ToF-SIMS) and X-ray photoelectron spectroscopy (XPS): detection of low amounts of adsorbed protein.
Wagner MS; McArthur SL; Shen M; Horbett TA; Castner DG
J Biomater Sci Polym Ed; 2002; 13(4):407-28. PubMed ID: 12160301
[TBL] [Abstract][Full Text] [Related]
18. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems.
Wendorf J; Chesko J; Kazzaz J; Ugozzoli M; Vajdy M; O'Hagan D; Singh M
Hum Vaccin; 2008; 4(1):44-9. PubMed ID: 18438105
[TBL] [Abstract][Full Text] [Related]
19. Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles.
Yeh MK; Coombes AG; Chen JL; Chiang CH
J Microencapsul; 2002; 19(5):671-82. PubMed ID: 12433308
[TBL] [Abstract][Full Text] [Related]
20. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles.
Malyala P; Chesko J; Ugozzoli M; Goodsell A; Zhou F; Vajdy M; O'Hagan DT; Singh M
J Pharm Sci; 2008 Mar; 97(3):1155-64. PubMed ID: 17683059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
